Navigation Links
European Journal of Heart Failure publishes new randomized controlled clinical study of RESPeRATE
Date:9/28/2011

Lod, Israel. September 27th, 2011 InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced that European Journal of Heart Failure, a peer reviewed medical journal of the European Society of Cardiology, published the results of a 72-patients, randomized, controlled study which demonstrated that deviceguided respiratory modulation with RESPeRATE applied at the home setting can significantly relieve symptoms of heart failure in elderly patients.

Chronic heart failure (CHF) affects about 5 million patients in the U.S. alone. It is the most widespread cause of hospitalization of patients over 65, with over 1 million hospitalizations every year. The total cost of treating the disease is estimated at $33 billion annually. About 91% of CHF sufferers have a medical history involving hypertension.

The study was conducted by Inger Ekman, MD, Professor of Medicine, Institute of Health and Care Sciences, the Sahlgrenska Academy, University of Gothenburg, Sweden with funding from the Swedish Heart Lung Foundation. It was found that after 4 weeks of twice daily 20 minute at-home treatment sessions with RESPeRATE, patients, who modified the breathing as directed by the device , demonstrated a reduction in the severity of CHF measured by New York Heart Association (NYHA) classification, and in dyspnea (shortness of breath) that is the major reason for seeking care in the CHF population. The observed reduction was significant by both its absolute mean and in comparison with control group and/or with patients, who didn't modify breathing as directed by the device.

"CHF is disabling and leads to decreased quality of life, frequent hospitalizations and poor survival. The patient's subjective response to the condition is associated with symptoms that reflect physical aspects as well as integrated aspects of lifestyle, anxiety, depression, and expectations of the patient. The device-guided respiratory modulation provided by the RESPeRATE might have the potential to relieve symptoms of heart failure in outpatients by changing their Device-guided respiratory modulation have the potential to relieve symptoms of heart failure in outpatients by changing their breathing pattern" said Prof. Ekman.

Results are consistent with those published last year in Circulation Heart Failure by Gianfranco Parati, Professor of Medicine from St. Luca Hospital, in Milano and his colleagues. That randomized controlled study with similar use of RESPeRATE at home over 8 weeks is feasible in patients with heart failure and systolic dysfunction and demonstrated significant improvement in clinically relevant parameters for, including CHF severity; left ventricular ejection fraction and pulmonary pressure and function.

"The positive effect of the RESPeRATE on CHF patients reported by these independent studies expand the growing body of scientific evidence that already has proven RESPeRATE as a clinically valid treatment for hypertension," said Erez Gavish, President and CEO of InterCure. "We plan to continue exploring the potential of RESPeRATE and our patented device-guided respiratory modulation technology to benefit patients with other cardiovascular diseases."

RESPeRATE is the only FDA-cleared, CE-marked device indicated for the adjunctive treatment of hypertension. RESPeRATE's clinical efficacy in lowering blood pressure has been validated in 10 separate published studies and 200,000 units have been sold to consumers. RESPeRATE has not been cleared for use in the treatment of heart failure in the United States, European Union or elsewhere.


'/>"/>

Contact: Tom Kirwan
tkirwan@intercure.com
347-528-7734
InterCure
Source:Eurekalert

Related medicine news :

1. Media have less than 3 weeks to register for the European Multidisciplinary Cancer Congress 2011
2. Treatment of rectal cancer varies enormously between different European countries
3. 2011 European Muldisciplinary Cancer Congress abstracts online Sept. 12
4. The first European registry to evaluate the real-life epidemiology of atrial fibrillation ablation
5. Americans No Longer Outliving Europeans: Study
6. The only European researcher to win this years Early Career Bayer Hemophilia Award is Portuguese
7. Research reveals that 10 percent of middle-aged Europeans are on antidepressants
8. Several methods for early diagnosis of Alzheimers disease developed by European scientists
9. Officials: U.S. Not Affected by European E. Coli Outbreak
10. European Society of Human Reproduction and Embryology Annual Meeting July 3-6, 2011, Stockholm
11. Clinical trials for new Alzheimers disease treatment to be awarded European Commission €6m funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may ... pelvic conditions and has helped many women become pregnant upon treating their diagnosis. ... office-based and simple outpatient evaluations. We can provide the necessary information to ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant ... produce more and better food, with fewer resources. It highlights the business’ principles, ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... proud to announce that it has received 510(k) clearance from the U.S. Food ... and the MyoCycle Pro. , Both devices are stationary cycling systems that use ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges the ... how his administration could impact the employee benefits industry. James Slotnick, AVP, Government ... likely to make it through Congress. His discussion will focus on the current ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  CVS Pharmacy, the retail division of CVS ... design to enhance the retail customer experience with ... and expanded beauty selections paired with informational signage ... offerings. Together with its innovative digital programs, these ... experience at CVS Pharmacy.  "Pharmacy ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology: